Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection

Catherine DeMarino, Angela Schwab, Michelle Pleet, Allison Mathiesen, Joel M. Friedman, Nazira El-Hage, Fatah Kashanchi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Despite the significant advances in neurological medicine, it remains difficult to treat ailments directly involving the brain. The blood brain barrier (BBB) is a tightly regulated, selectively permeable barrier that restricts access from the blood into the brain extracellular fluid (BEF). Many conditions such as tumors or infections in the brain are difficult to treat due to the fact that drugs and other therapeutic agents are unable to easily pass through this relatively impermeable barrier. Human Immunodeficiency Virus (HIV) presents a particular problem as it is able to remain dormant in the brain for years protected from antiretroviral drugs by the BBB. The development of nanoscale carriers over the past few decades has made possible the delivery of therapies with the potential to overcome membrane barriers and provide specific, targeted delivery. This review seeks to provide a comprehensive overview of the various aspects of nanoparticle formulation and their applications in improving the delivery efficiency of drugs, specifically antiretroviral therapeutics to the brain to treat HIV.

Original languageEnglish (US)
Pages (from-to)1-20
Number of pages20
JournalJournal of NeuroImmune Pharmacology
DOIs
StateAccepted/In press - Jul 2 2016

Fingerprint

Nanoparticles
Brain
Infection
Blood-Brain Barrier
HIV
Pharmaceutical Preparations
Therapeutics
Extracellular Fluid
Medicine
Membranes
Neoplasms

Keywords

  • CNS
  • Drug delivery
  • Exosomes
  • HIV
  • Nanoparticles

ASJC Scopus subject areas

  • Pharmacology
  • Immunology and Allergy
  • Immunology
  • Neuroscience (miscellaneous)

Cite this

DeMarino, C., Schwab, A., Pleet, M., Mathiesen, A., Friedman, J. M., El-Hage, N., & Kashanchi, F. (Accepted/In press). Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection. Journal of NeuroImmune Pharmacology, 1-20. https://doi.org/10.1007/s11481-016-9692-7

Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection. / DeMarino, Catherine; Schwab, Angela; Pleet, Michelle; Mathiesen, Allison; Friedman, Joel M.; El-Hage, Nazira; Kashanchi, Fatah.

In: Journal of NeuroImmune Pharmacology, 02.07.2016, p. 1-20.

Research output: Contribution to journalArticle

DeMarino, Catherine ; Schwab, Angela ; Pleet, Michelle ; Mathiesen, Allison ; Friedman, Joel M. ; El-Hage, Nazira ; Kashanchi, Fatah. / Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection. In: Journal of NeuroImmune Pharmacology. 2016 ; pp. 1-20.
@article{dfbcd9d3fac44797b8a04ee9f7218bd5,
title = "Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection",
abstract = "Despite the significant advances in neurological medicine, it remains difficult to treat ailments directly involving the brain. The blood brain barrier (BBB) is a tightly regulated, selectively permeable barrier that restricts access from the blood into the brain extracellular fluid (BEF). Many conditions such as tumors or infections in the brain are difficult to treat due to the fact that drugs and other therapeutic agents are unable to easily pass through this relatively impermeable barrier. Human Immunodeficiency Virus (HIV) presents a particular problem as it is able to remain dormant in the brain for years protected from antiretroviral drugs by the BBB. The development of nanoscale carriers over the past few decades has made possible the delivery of therapies with the potential to overcome membrane barriers and provide specific, targeted delivery. This review seeks to provide a comprehensive overview of the various aspects of nanoparticle formulation and their applications in improving the delivery efficiency of drugs, specifically antiretroviral therapeutics to the brain to treat HIV.",
keywords = "CNS, Drug delivery, Exosomes, HIV, Nanoparticles",
author = "Catherine DeMarino and Angela Schwab and Michelle Pleet and Allison Mathiesen and Friedman, {Joel M.} and Nazira El-Hage and Fatah Kashanchi",
year = "2016",
month = "7",
day = "2",
doi = "10.1007/s11481-016-9692-7",
language = "English (US)",
pages = "1--20",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",

}

TY - JOUR

T1 - Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection

AU - DeMarino, Catherine

AU - Schwab, Angela

AU - Pleet, Michelle

AU - Mathiesen, Allison

AU - Friedman, Joel M.

AU - El-Hage, Nazira

AU - Kashanchi, Fatah

PY - 2016/7/2

Y1 - 2016/7/2

N2 - Despite the significant advances in neurological medicine, it remains difficult to treat ailments directly involving the brain. The blood brain barrier (BBB) is a tightly regulated, selectively permeable barrier that restricts access from the blood into the brain extracellular fluid (BEF). Many conditions such as tumors or infections in the brain are difficult to treat due to the fact that drugs and other therapeutic agents are unable to easily pass through this relatively impermeable barrier. Human Immunodeficiency Virus (HIV) presents a particular problem as it is able to remain dormant in the brain for years protected from antiretroviral drugs by the BBB. The development of nanoscale carriers over the past few decades has made possible the delivery of therapies with the potential to overcome membrane barriers and provide specific, targeted delivery. This review seeks to provide a comprehensive overview of the various aspects of nanoparticle formulation and their applications in improving the delivery efficiency of drugs, specifically antiretroviral therapeutics to the brain to treat HIV.

AB - Despite the significant advances in neurological medicine, it remains difficult to treat ailments directly involving the brain. The blood brain barrier (BBB) is a tightly regulated, selectively permeable barrier that restricts access from the blood into the brain extracellular fluid (BEF). Many conditions such as tumors or infections in the brain are difficult to treat due to the fact that drugs and other therapeutic agents are unable to easily pass through this relatively impermeable barrier. Human Immunodeficiency Virus (HIV) presents a particular problem as it is able to remain dormant in the brain for years protected from antiretroviral drugs by the BBB. The development of nanoscale carriers over the past few decades has made possible the delivery of therapies with the potential to overcome membrane barriers and provide specific, targeted delivery. This review seeks to provide a comprehensive overview of the various aspects of nanoparticle formulation and their applications in improving the delivery efficiency of drugs, specifically antiretroviral therapeutics to the brain to treat HIV.

KW - CNS

KW - Drug delivery

KW - Exosomes

KW - HIV

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84976509908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976509908&partnerID=8YFLogxK

U2 - 10.1007/s11481-016-9692-7

DO - 10.1007/s11481-016-9692-7

M3 - Article

SP - 1

EP - 20

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

ER -